Low-Grade Appendiceal Mucinous Neoplasm Masquerading as Acute Appendicitis: Diagnostic Challenges, Surgical Management, and Surveillance Strategies
Low-grade appendiceal mucinous neoplasm (LAMN) often presents as an acute abdomen, masking its true nature behind the clinical symptoms of common appendicitis.
While standard appendectomy resolves the immediate infection, the presence of these rare tumors requires precise surgical and diagnostic decision-making to avoid both undertreatment and unnecessary radical surgery.
Key Clinical Takeaways:
- Preoperative CT scans frequently fail to identify LAMN, detecting tumors in only 3.4% of invasive and 16% of noninvasive cases.
- Intraoperative identification of an abnormally dilated or enlarged appendix is the most critical indicator for potential neoplasia.
- Complete surgical excision with negative margins is generally curative for localized, nonperforated LAMN, often precluding the need for more extensive procedures like right hemicolectomy.
Diagnostic Challenges in Acute Presentations
Distinguishing uncomplicated appendicitis from an underlying mucinous neoplasm is still a major diagnostic challenge. According to a cohort study of 5,224 patients published in Cureus, preoperative imaging often lacks the specificity to distinguish cystic appendiceal lesions from inflammatory changes.
The study said that radiologists suspected a tumor in only a small fraction of cases prior to surgery, meaning the diagnosis is frequently established only when a surgeon observes a markedly dilated appendix during an operation.
When an appendiceal neoplasm is suspected intraoperatively, the goal shifts to achieving complete oncologic resection while sparing the patient from the morbidity of an unnecessary right hemicolectomy. Clinical evidence suggests that for LAMN confined to the appendix, a partial cecectomy or standard appendectomy is often sufficient provided the surgical margins are clear.
A recent systematic review found no evidence of lymph-node metastases in patients with nondisseminated LAMN, reinforcing the American Society of Colon and Rectal Surgeons guidelines that support avoiding routine completion colectomy in appropriately selected patients.
Pathologic Staging and Risk Stratification
Histopathologic evaluation serves as the definitive tool for staging and determining the necessity of further intervention. Unlike adenocarcinoma, LAMN is characterized by expansile growth and low-grade cytologic atypia, as detailed in the American Joint Committee on Cancer (AJCC) staging guidelines.
Surgeons and pathologists must examine the specimen closely for perforation or extra-appendiceal mucin, as these factors greatly raise the risk of pseudomyxoma peritonei — a condition where mucinous tumor cells spread through the peritoneal cavity.
| Risk Factor | 10-Year Cumulative Recurrence Risk |
|---|---|
| Presence of Risk Factors (Size > 2cm or RLQ involvement) | 30% |
| Absence of Risk Factors | 1% |
Individualized Surveillance Strategies
Postoperative surveillance protocols remain a subject of debate due to the varying risk of disease progression. A 2024 study from the Mayo Clinic identified that tumor size and the extent of disease involvement are primary predictors of recurrence. While some low-risk patients may require minimal follow-up, those with specific high-risk pathologic features benefit from structured imaging.
In cases where the tumor is fully excised and no extra-appendiceal spread is noted, frequent imaging often provides minimal clinical benefit. Patients should discuss their specific pathologic report with a board-certified surgical oncologist or a colorectal surgeon to determine if a specialized follow-up schedule is required based on their tumor markers and staging.
The long-term prognosis for patients with localized, nonperforated LAMN and negative surgical margins remains excellent, with many patients showing no evidence of recurrence years after the initial procedure.
The clinical community continues to evaluate whether a universal surveillance timeline can be established or if management must remain strictly tailored to the individual’s pathologic findings. Without standardized protocols, the decision to continue imaging depends on the excised tumor's specific features and any high-risk markers the pathology team identifies.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.